STRONTIUM-CONTAINING COMPLEXES FOR TREATING GASTROESOPHAGEAL REFLUX AND BARRETT'S ESOPHAGUS
Therapeutically-active compositions for treating pain, irritation, and inflammation associated with gastroesophageal reflux and Barrett's esophagus that combines at least one acid neutralizing strontium salt with at least one polyhydroxyphenol, at least one polymer, and optionally at least one cysteine based antioxidant.
1 . A composition for treating gastroesophageal reflux comprising:
(a) at least one acid neutralizing strontium salt selected from the group consisting of: strontium carbonate, strontium bicarbonate, strontium hydroxide, strontium phosphate, and strontium citrate;
(b) at least one polyhydroxyphenol selected from the group consisting of: gallic acid, tannic acid, pentagalloyl glucose, ellagic acid, and esters thereof; and
(c) at least one polymer selected from the group consisting of alginic acid, polyvinylpyrrolidone, and xanthan gum.
2 - 18 . (canceled)
19 . A composition for treating gastroesophageal reflux comprising:
(a) at least one acid neutralizing strontium salt selected from the group consisting of:
strontium carbonate, strontium bicarbonate, strontium hydroxide, strontium phosphate, and strontium citrate;
(b) at least one polyhydroxyphenol selected from the group consisting of: gallic acid, tannic acid, pentagalloyl glucose, ellagic acid, and esters thereof;
(c) at least one cysteine based antioxidant selected from the group consisting of cystine and N,S-diacetylcysteine; and
(d) at least one polymer selected from the group consisting of alginic acid, polyvinylpyrrolidone, and xanthan gum.
20 - 42 . (canceled)
43 . The composition of claim 1 , further comprising at least one additional acid neutralizing agent.
44 . The composition of claim 43 , wherein the acid neutralizing agent is selected from the group consisting of calcium carbonate, sodium bicarbonate, sodium citrate, aluminum hydroxide, aluminum phosphate, magnesium hydroxide, magnesium carbonate, magaldrate, almagate, and hydrotalcite.
45 - 55 . (canceled)
56 . The composition of claim 1 , further comprising a histamine H2 receptor antagonist.
57 . The composition of claim 56 , wherein the histamine H2 receptor antagonist is selected from the group consisting of cimetidine, famotidine, nizatidine, and ranitidine.
58 - 61 . (canceled)
62 . The composition of claim 1 , further comprising a proton pump inhibitor.
63 . The composition of claim 62 , wherein the proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole.
64 - 71 . (canceled)
72 . A method of treating heartburn or gastroesophageal reflux disease comprising administering the composition of claim 1 to a patient.
73 . The method of claim 72 , wherein the composition is administered to the patient after eating but before onset of gastroesophageal reflux symptoms.
74 - 75 . (canceled)
76 . The method of claim 72 , wherein the composition is administered to the patient upon presentation of gastroesophageal reflux symptoms.
77 . The composition of claim 19 , further comprising at least one additional acid neutralizing agent.
78 . The composition of claim 77 , wherein the acid neutralizing agent is selected from the group consisting of calcium carbonate, sodium bicarbonate, sodium citrate, aluminum hydroxide, aluminum phosphate, magnesium hydroxide, magnesium carbonate, magaldrate, almagate, and hydrotalcite.
79 . The composition of claim 19 , further comprising a histamine H2 receptor antagonist.
80 . The composition of claim 79 , wherein the histamine H2 receptor antagonist is selected from the group consisting of cimetidine, famotidine, nizatidine, and ranitidine.
81 . The composition of claim 19 , further comprising a proton pump inhibitor.
82 . The composition of claim 81 , wherein the proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole.
83 . A method of treating heartburn or gastroesophageal reflux disease comprising administering the composition of claim 19 to a patient.
84 . The method of claim 83 , wherein the composition is administered to the patient after eating but before onset of gastroesophageal reflux symptoms.
85 . The method of claim 83 , wherein the composition is administered to the patient upon presentation of gastroesophageal reflux symptoms.